“诊断性”TURP在BPH伴血清PSA异常患者中的应用价值

袁祖亮; 李文成; 贾瑞鹏; 许露伟; 徐郑; 梁凯; 吴剑平; 窦全亮; 朱佳庚; 苏江浩

“诊断性”TURP在BPH伴血清PSA异常患者中的应用价值

- 南京医科大学附属南京医院泌尿外科(南京, 210006)

详细信息

通讯作者: 贾瑞鹏,E-mail:urologist025@sohu.com

中图分类号: R697

收稿日期: 2012-10-03

The Role of diagnostic TURP in patients with elevated serum PSA levels BPH

- Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China

More Information

Corresponding author: JIA Ruipeng, E-mail: urologist025@sohu.com

Received Date: 03 October 2012

摘要

摘要: 目的：探讨"诊断性"TURP在BPH伴血清PSA异常患者中的应用价值及意义。方法：对BPH伴血清PSA异常患者行"诊断性"TURP，然后对手术切除的前列腺组织行病理检查，按照病理诊断结果分为PCa组和BPH组，分别评估PCa组患者的临床分期及Gleason评分和BPH组患者TURP术后3个月、6个月、1年及随访结束时血清PSA、IPSS评分、生活质量等。结果：87例BPH伴血清PSA异常者行"诊断性"TURP，病理诊断为PCa 5例，Gleason评分5~8分，肿瘤分期T_1a~T_2a，行PCa根治性切除术；病理诊断为BPH 82例，出院后均随访2~4年，其中血清PSA恢复正常者77例，显著下降者3例，持续异常者2例，IPSS评分均有明显降低。结论：对血清PSA异常患者，"诊断性"TURP可有助于诊断PCa并对下尿路症状的改善和血清PSA的正常化具重要作用。
- 前列腺特异性抗原 /
- 诊断性电切 /
- 前列腺癌 /
- 前列腺增生
Abstract: Objective: To evaluate the value and significance of diagnostic transurethral resection of the prostate(TURP) in the patients with persistently abnormal serum PSA levels. Methods: BPH patients with elevated serum PSA levels (>4 μg/L) underwent TURP. According to pathological examination of prostate tissue removed in TURP, we divided the patients into the PCa group and BPH group. Gleason score, clinical stage were evaluated for PCa patients, serum PSA testing and the International Prostate Symptom Score (IPSS) etc were evaluated for BPH patients every three months, six months and one year respectively. Results: Of 87 patients, 82 cases were diagnosed as BPH by pathological examination postoperatively, 5 cases were PCa, Gleason score 5-8, tumor stage T_1a-T_2a and radical prostatectomy was done. Followed up 2-4 years, 77 patients have normal serum PSA, 3 serum PSA reduced greatly, 2 persistently abnormal serum PSA, IPSS for all patients reduced greatly. Conclusion: Diagnostic TURP can be used as an important method in the diagnosis of patients with elevated serum PSA levels. Also the lower urinary tract symptoms could be relieved by TURP and serum PSA could recover to normal level.
- prostate specific antigen /
- diagnotic transurethral resection of the prostate /
- prostate cancer /
- benign prostatic hyperplasia

HTML全文

参考文献(16)

[1]	Thompson I M, Pauler D K, Goodman P J, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or=4.0 ng per milliliter[J]. N Engl J Med, 2004, 350:2239-2246.
[2]	Roehl K A, Antenor J A, Catalona W J. Serial biopsy results in prostate cancer screening study[J]. J Urol, 2002, 167:2435-2439.
[3]	Pepe P, Dibenedetto G, Gulletta M, et al. Prostate cancer detection after one or more negative extended needle biopsy:results of a multicenter case-findings protocol[J]. Arch Ital Urol Androl, 2010, 82:95-99.
[4]	那彦群,叶章群,孙光主编. 中国泌尿外科疾病诊断治疗指南(2011版)[M]. 北京:人民卫生出版社, 2011:128-129.
[5]	Radhakrishnan S, Dorkin T J, Sheikh N, et al. Role of transition zone sampling by TURP in patients with raised PSA and multiple negative transrectal ultrasound-guided prostatic biopsies.[J]. Prostate Cancer Prostatic Dis, 2004, 7:338-342.
[6]	Pepe P, Candiano G, Fraqqetta F, et al. Is transition zone sampling at repeated saturation prostate biopsy still useful[J]? Urol Int, 2010, 85:324-327.
[7]	Chen Y T, Chiang P H, Hsu C C, et al. Simultaneous transurethral resection of prostate and prostate needle biopsy in patients with acute urinary retention and elevated prostate specific antigen levels[J]. Chang Gung Med J, 2009, 32:417-422.
[8]	Roehrborn C G, McConnell J D, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia[J]. J Urol, 1999, 53:473-480.
[9]	Semjonow A, De Angelis G, Oberpenning F, et al. The clinical impact of different assays for prostate specific antigen[J]. BJU Int, 2000, 86:590-597.
[10]	Onder A U, Yalcin V, Arar O, et al. Impact 0f trallsiIion zone biopsies in detection and evaluation of prostate cancer[J]. Eur Urol, 1998, 33:542-548.
[11]	Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4:when should we stop[J]? J Urol, 2001, 166:1679-1683.
[12]	Mochtar C A, Kiemeney L A, Van Riemsdijk M M, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia[J]. Eur Urol, 2003, 44:695-700.
[13]	Collins G N, Alexandrou K, Wynn-Davies A, et al. Free prostate-specific antigen "in the field":a useful adjunct to standard clinical practice[J]. BJU Int, 1999, 83:1000-1002.
[14]	van Renterghem K, van Koeveringe G, Achten R, et al. Long-term clinical outcome of diagnostic transurethral resection of the prostate in patients with elevated prostate-specific antigen level and minor lower urinary tract symptoms[J]. Urol Int, 2009, 83:60-65.
[15]	van Renterghem K, van Koeveringe G, Achten R, et al.Prospective study of the role of transurethral resection of the prostate in patients with an elevated prostate-specific antigen level, minor lower urinary tract symptoms, and proven bladder outlet obstruction[J]. Eur Urol, 2008, 54:1385-1392.
[16]	Van Renterghem K M, Van Kerrebroeck P E, Van Koeveringe G A, et al. Role and current situation of TURP in patients with elevated PSA[J]. Arch Esp Urol, 2010, 63:411-419.